ClinicalTrials.gg
CompletedNCT00359905Updated Feb 19, 2009

Evaluation of the Efficacy and Safety of Silodosin in the Treatment of the Signs and Symptoms of BPH

A Phase 3 interventional study of Silodosin and Tamsulosin in Benign Prostatic Hyperplasia, sponsored by RECORDATI GROUP. Completed at 1 site in United Kingdom. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2009-02-19.

Sponsored by RECORDATI GROUP · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,228
Allocation
Randomized
Ages
50 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing silodosin in Prostatic Hyperplasia — 4 open to participants now, 4 under way, none of them phase 3. silodosin · Prostatic Hyperplasia.

Enrollment
Largest of 19
1,228 · median 141
Started
2006
the only one that year
Phase 3
4 of 19
none open now
Registered
4th of 19
by date
Lead sponsor
2 of 19
RECORDATI GROUP

Among the 19 studies testing silodosin in Prostatic Hyperplasia, this one has the largest enrollment, is the only one that started in 2006, is one of 4 in phase 3, and was the 4th registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

4 of the 19 studies testing silodosin in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About silodosin

silodosin: first FDA approval 2008 (RAPAFLO), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 50 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing silodosin in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

A new drug for the treatment of benign prostatic hyperplasia is compared with placebo and tamsulosin (a drug belonging to the same therapeutic class) for to determine if it is safe and effective (the first phase of the study lasts approximately 18 weeks) and then is used for another 9 months to determine its long-term safety.

Read the detailed description

This is a multi-centre, double-blind, placebo and active controlled, parallel 12 week treatment trial in men with signs and symptoms of benign prostatic hyperplasia, followed by a 9 month open-label phase. The following procedures are used: physical exams, electrocardiograms, clinical laboratory tests, vital signs, the International Prostate Symptom Score, maximum urine flow rate, adverse events, concomitant medications, quality of life and compliance. 93 centres in 11 European countries (Finland, France, Germany, Italy, Netherlands, Poland, Romania, Russia, Spain, Ukraine, UK) will be involved

03

Conditions studied

  • Benign Prostatic Hyperplasia

Browse trials for

Keywords

  • Benign prostatic hyperplasia
  • alpha-blockers
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males in good general health and at least 50 years of age, with symptoms of moderate to severe Benign Prostatic Hyperplasia

Exclusion criteria

Exclusion Criteria:

  • Medical conditions that would confound the efficacy evaluation
  • Medical conditions in which it would be unsafe to use an alpha-blocker
  • Use of concomitant drugs that would confound the efficacy evaluation
  • Use of concomitant drugs that would be unsafe with this alpha-blocker
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,228 participants (actual)

Study arms

  • Experimental
    Silodosin

    Drug: Silodosin

  • Active comparator
    Tamsulosin

    Drug: Tamsulosin

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • 8 mg daily for 12 weeks

    Also known as: KMD3213

  • 0.4 mg daily for 12 weeks

    Also known as: Omnic

  • DrugPlacebo

    once daily for 12 weeks

06

What researchers measure

Primary outcomes

  1. Change in baseline total score on the International Prostate Symptom Score

    Time frame: 12 weeks

Secondary outcomes

  1. Change in baseline obstructive subscore of the International Prostate Symptom Score;

    Time frame: 12 weeks

  2. change in baseline irritative subscore of the International Prostate Symptom Score;

    Time frame: 12 weeks

  3. change in baseline maximum urine flow rate;

    Time frame: 12 weeks

  4. safety

    Time frame: 52 weeks

07

Study locations

1 site
  • Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital
    Sheffield, S10 2JF, United Kingdom
08

References and documents

Publications

  • Osman NI, Chapple CR, Tammela TL, Eisenhardt A, Oelke M. Open-label, 9-month extension study investigating the uro-selective alpha-blocker silodosin in men with LUTS associated with BPH. World J Urol. 2015 May;33(5):697-706. doi: 10.1007/s00345-015-1519-2. Epub 2015 Feb 25. PubMed 25712312 ↗
  • Chapple CR, Montorsi F, Tammela TL, Wirth M, Koldewijn E, Fernandez Fernandez E; European Silodosin Study Group. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol. 2011 Mar;59(3):342-52. doi: 10.1016/j.eururo.2010.10.046. Epub 2010 Nov 10. PubMed 21109344 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of May 2007 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2006
First posted
Aug 3, 2006
Start
May 2006
Primary completionActual
May 2007
CompletionActual
Jan 2008
Last update
Feb 19, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00359905
Lead sponsor
RECORDATI GROUP
First posted
Aug 3, 2006
Start date
May 2006
Primary completion
May 2007
Completion
Jan 2008
Last update
Feb 19, 2009

Study contacts

Christopher Re Chapple, BSc MD
principal investigator · Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Silodosin

Start the discussion